Study comparing the double kissing (DK) crush with classical crush for the treatment of coronary bifurcation lesions: the DKCRUSH-1 Bifurcation Study with drug-eluting stents.
BACKGROUND
Classical crush has a lower rate of final kissing balloon inflation (FKBI) immediately after percutaneous coronary intervention (PCI). The double kissing (DK) crush technique has the potential to increase the FKBI rate, and no prospective studies on the comparison of classical with DK crush techniques have been reported.


METHODS
Three hundred and eleven patients with true bifurcation lesions were randomly divided into classical (n = 156) and DK crush (n = 155) groups. Clinical and angiographic details at follow-up at 8 months were indexed. The primary end point was major adverse cardiac events (MACE) including myocardial infarction, cardiac death and target lesion revascularization (TLR) at 8 months.


RESULTS
FKBI was 76% in the classical crush group and 100% in the DK group (P < 0.001). The incidence of stent thrombosis was 3.2% in the classical crush group (5.1% in without- and 1.7% in with-FKBI) and 1.3% in the DK crush group. Cumulative 8 month MACE was 24.4% in the classical crush group and 11.4% in the DK crush group (P = 0.02). The TLR-free survival rate was 75.4% in the classical crush group and 89.5% in the DK crush group (P = 0.002).


CONCLUSIONS
DK crush technique has the potential of increasing FKBI rate and reducing stent thrombosis, with a further reduction of TLR and cumulative MACE rate at 8 months.
Chen
S L
SL
Cardiological Department, Nanjing First Hospital of Nanjing Medical University, Nanjing, China. chmengx@126.com
Zhang
J J
JJ
Ye
F
F
Chen
Y D
YD
Patel
T
T
Kawajiri
K
K
Lee
M
M
Kwan
T W
TW
Mintz
G
G
Tan
H C
HC
D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003330:Coronary Vessel Anomalies / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use; D016016:Proportional Hazards Models; D011446:Prospective Studies; D019919:Prosthesis Implantation / Q000379:methods*; D012008:Recurrence; D020123:Sirolimus / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D017239:Paclitaxel; D020123:Sirolimus